Interim thymus and activation regulated chemokine versus interim F-18-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation

Wouter J Plattel; Lydia Visser; Arjan Diepstra; Andor W J M Glaudemans; Marcel Nijland; Tom van Meerten; Hanneke C Kluin-Nelemans; Gustaaf W van Imhoff; Anke van den Berg

doi:10.1111/bjh.16514

Interim thymus and activation regulated chemokine versus interim F-18-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation

Wouter J Plattel^*, Lydia Visser, Arjan Diepstra, Andor W J M Glaudemans, Marcel Nijland, Tom van Meerten, Hanneke C Kluin-Nelemans, Gustaaf W van Imhoff, Anke van den Berg

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

17 Citations (Scopus)

220 Downloads (Pure)

Abstract

Serum thymus and activation regulated chemokine (TARC) levels reflect classical Hodgkin lymphoma (cHL) disease activity and correspond with treatment response. We compared mid-treatment interim TARC (iTARC) with interim 18 F-fluorodeoxyglucose positron-emission tomography (iPET) imaging to predict modified progression-free survival (mPFS) in a group of 95 patients with cHL. High iTARC levels were found in nine and positive iPET in 17 patients. The positive predictive value (PPV) of iTARC for a 5-year mPFS event was 88% compared to 47% for iPET. The negative predictive value was comparable at 86% for iTARC and 85% for iPET. Serum iTARC levels more accurately reflect treatment response with a higher PPV compared to iPET.

Original language	English
Pages (from-to)	40-44
Number of pages	5
Journal	British Journal of Haematology
Volume	190
Issue number	1
DOIs	https://doi.org/10.1111/bjh.16514
Publication status	Published - 1-Jul-2020

Keywords

ADAPTED TREATMENT
PET
ABVD
BIOMARKERS
TRIAL
TARC

Access to Document

10.1111/bjh.16514Licence: CC BY-NC-ND

Interim thymus and activation regulated chemokine versus interim 18F‐fluorodeoxyglucose positron‐emission tomography in classical Hodgkin lymphoma response evaluationFinal publisher's version, 142 KBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

Plattel, W. J., Visser, L., Diepstra, A., Glaudemans, A. W. J. M., Nijland, M., van Meerten, T., Kluin-Nelemans, H. C., van Imhoff, G. W., & van den Berg, A. (2020). Interim thymus and activation regulated chemokine versus interim F-18-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation. British Journal of Haematology, 190(1), 40-44. https://doi.org/10.1111/bjh.16514

@article{b55ab40b98654825a1c6e8df5fd4118e,

title = "Interim thymus and activation regulated chemokine versus interim F-18-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation",

abstract = "Serum thymus and activation regulated chemokine (TARC) levels reflect classical Hodgkin lymphoma (cHL) disease activity and correspond with treatment response. We compared mid-treatment interim TARC (iTARC) with interim 18 F-fluorodeoxyglucose positron-emission tomography (iPET) imaging to predict modified progression-free survival (mPFS) in a group of 95 patients with cHL. High iTARC levels were found in nine and positive iPET in 17 patients. The positive predictive value (PPV) of iTARC for a 5-year mPFS event was 88% compared to 47% for iPET. The negative predictive value was comparable at 86% for iTARC and 85% for iPET. Serum iTARC levels more accurately reflect treatment response with a higher PPV compared to iPET.",

keywords = "ADAPTED TREATMENT, PET, ABVD, BIOMARKERS, TRIAL, TARC",

author = "Plattel, {Wouter J} and Lydia Visser and Arjan Diepstra and Glaudemans, {Andor W J M} and Marcel Nijland and {van Meerten}, Tom and Kluin-Nelemans, {Hanneke C} and {van Imhoff}, {Gustaaf W} and {van den Berg}, Anke",

note = "{\textcopyright} 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.",

year = "2020",

month = jul,

day = "1",

doi = "10.1111/bjh.16514",

language = "English",

volume = "190",

pages = "40--44",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley",

number = "1",

}

Plattel, WJ , Visser, L , Diepstra, A , Glaudemans, AWJM , Nijland, M , van Meerten, T , Kluin-Nelemans, HC , van Imhoff, GW & van den Berg, A 2020, 'Interim thymus and activation regulated chemokine versus interim F-18-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation', British Journal of Haematology, vol. 190, no. 1, pp. 40-44. https://doi.org/10.1111/bjh.16514

Interim thymus and activation regulated chemokine versus interim F-18-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation. / Plattel, Wouter J ; Visser, Lydia ; Diepstra, Arjan et al.
In: British Journal of Haematology, Vol. 190, No. 1, 01.07.2020, p. 40-44.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Interim thymus and activation regulated chemokine versus interim F-18-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation

AU - Plattel, Wouter J

AU - Visser, Lydia

AU - Diepstra, Arjan

AU - Glaudemans, Andor W J M

AU - Nijland, Marcel

AU - van Meerten, Tom

AU - Kluin-Nelemans, Hanneke C

AU - van Imhoff, Gustaaf W

AU - van den Berg, Anke

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Serum thymus and activation regulated chemokine (TARC) levels reflect classical Hodgkin lymphoma (cHL) disease activity and correspond with treatment response. We compared mid-treatment interim TARC (iTARC) with interim 18 F-fluorodeoxyglucose positron-emission tomography (iPET) imaging to predict modified progression-free survival (mPFS) in a group of 95 patients with cHL. High iTARC levels were found in nine and positive iPET in 17 patients. The positive predictive value (PPV) of iTARC for a 5-year mPFS event was 88% compared to 47% for iPET. The negative predictive value was comparable at 86% for iTARC and 85% for iPET. Serum iTARC levels more accurately reflect treatment response with a higher PPV compared to iPET.

AB - Serum thymus and activation regulated chemokine (TARC) levels reflect classical Hodgkin lymphoma (cHL) disease activity and correspond with treatment response. We compared mid-treatment interim TARC (iTARC) with interim 18 F-fluorodeoxyglucose positron-emission tomography (iPET) imaging to predict modified progression-free survival (mPFS) in a group of 95 patients with cHL. High iTARC levels were found in nine and positive iPET in 17 patients. The positive predictive value (PPV) of iTARC for a 5-year mPFS event was 88% compared to 47% for iPET. The negative predictive value was comparable at 86% for iTARC and 85% for iPET. Serum iTARC levels more accurately reflect treatment response with a higher PPV compared to iPET.

KW - ADAPTED TREATMENT

KW - PET

KW - ABVD

KW - BIOMARKERS

KW - TRIAL

KW - TARC

U2 - 10.1111/bjh.16514

DO - 10.1111/bjh.16514

M3 - Article

C2 - 32106342

SN - 0007-1048

VL - 190

SP - 40

EP - 44

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Interim thymus and activation regulated chemokine versus interim F-18-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this